Bulk Manufacturer of Controlled Substances Application: Promega Corporation
Published Date: 2/2/2026
Notice
Summary
Promega Corporation wants to make large amounts of psilocybin and psilocyn, two controlled substances, to sell as ingredients for medicines. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 3, 2026. This move could boost medicine development but also means Promega will handle some powerful substances under strict rules.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Promega Seeks to Make Schedule I APIs
On January 7, 2026, Promega Corporation (3075 Sub Zero Parkway, Fitchburg, Wisconsin) applied to be registered to bulk manufacture psilocybin (code 7437) and psilocyn (code 7438), both listed as Schedule I. The company says it plans to make these substances as Active Pharmaceutical Ingredients (APIs) for sale to its customers, and the registration would not authorize any other activities for those drug codes. Comments or requests for a hearing are due by April 3, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06523 — Designation of P2P Methyl Glycidic Acid as a List I Chemical
Starting May 4, 2026, anyone handling P2P methyl glycidic acid—a key chemical used to make illegal drugs like methamphetamine—must follow new government rules and register with the DEA. This means all transactions, big or small, will be closely watched to stop illegal drug production. Businesses dealing with this chemical should act fast to stay legal and avoid penalties.
2026-06521 — Importer of Controlled Substances Application: Lipomed/LGC Standards
Lipomed/LGC Standards wants to become an official importer of certain controlled substances, like 3-Fluoro-N-methylcathinone. This means companies involved with these drugs can comment or ask for a hearing by May 4, 2026. If approved, it could impact how these substances enter the U.S., but no direct costs are mentioned yet.
2026-06051 — Importer of Controlled Substances Application: Usona Institute
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
2026-05912 — Bulk Manufacturer of Controlled Substances Application: SpecGx LLC
SpecGx LLC wants to become a big-time maker of some powerful and tightly controlled drugs, including things like psilocybin and fentanyl. People and companies already registered can share their thoughts or ask for a hearing by May 26, 2026. This move could shake up how these substances are made and handled, so keep an eye on the deadlines if you’re involved!
2026-05618 — Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.
2026-05486 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!
Previous / Next Documents
Previous: 2026-01939 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on May 12, 2026, with part of it open to the public and part closed to protect private info and trade secrets. They’ll review grant applications in the closed session and discuss programs openly afterward. Anyone can watch the open part online and send in comments up to 15 days before the meeting.
Next: 2026-01941 — Center for Scientific Review; Notice of Closed Meeting
The NIH’s Center for Scientific Review is holding a secret virtual meeting on February 19, 2026, to review important grant applications about brain aging and cognitive disorders. This meeting was delayed by a government shutdown but is now urgent to keep research funding on track. Scientists and public health depend on these quick decisions to support vital medical research.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in